Wexford Capital’s Vor Biopharma VOR Stock Holding History

Wexford Capital’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-503	Closed	-$22.6K	–	288
2023 Q4	$22.6K	Buy	+503	New	+$20.8K	﹤0.01%	185

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wexford Capital's VOR Position: Q1 2024 in Review

Wexford Capital sold out of Vor Biopharma (VOR) in Q1 2024, closing a stake of 503 shares — an estimated $22.6K sold.

Wexford Capital first reported a position in VOR in Q4 2023 and held it in 1 quarter. The position peaked at $22.6K in Q4 2023. 68 funds tracked by Wall St. Rank hold VOR as of Q1 2024.

Wexford Capital reported no remaining Vor Biopharma position as of Q1 2024 after selling out during the quarter.
Wexford Capital sold 503 Vor Biopharma shares in Q1 2024, an estimated $22.6K.
Wexford Capital first reported a position in Vor Biopharma in Q4 2023 and held it in 1 quarter.
Wexford Capital's Vor Biopharma position peaked at $22.6K in Q4 2023.
68 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2024.

Based on Wexford Capital's 13F filing for Q1 2024, filed 15 May 2024.